WestCann brings THC & CBD hemp cigarettes to the U.S. and Canadian markets
Ryan Allway
October 21st, 2021
News, Top Story
The global cannabis industry is projected to reach nearly $20 billion in value this year and grow at a 27% compound annual growth rate through 2030, according to Quince Market Insights. But rather than focusing on industry giants, investors may want to take a closer look at niche corners of the market where innovators could unlock significant value.
For example, WestCann has developed tobacco and nicotine-free cigarettes in the U.S. and THC cigarettes in Canada. The business model combines tobacco alternatives, like the products produced by TAAT Global Alternatives Inc. (CSE:TAAT), which has a ~$320 million market capitalization, with Canada’s recreational cannabis momentum.
Let’s take a look at WestCann’s fresh approach to the market, why it’s uniquely qualified to execute on its vision, and how you can invest now (if you are an accredited investor) or when it goes public on the Canadian Securities Exchange (CSE) in Q1 2022.
Smoking Cessation & Recreation
The global market for smoking cessation and nicotine de-addiction products is forecast to reach nearly $40 billion by 2027, according to iHealthcareAnalyst, representing a 15.6% compound annual growth rate. Yet, despite a growing number of smoking cessation products, relapse rates remain depressingly high even after five years of abstinence.
WestCann is a pioneer in developing CBD cigarettes in the U.S., providing a better alternative for those looking to quit tobacco. Its LAIKA brand tobacco- and nicotine-free hemp cigarettes closely replicate the sensory elements of tobacco cigarettes, providing a pleasant and satisfying consumer experience without the harmful additives.
Across the border, WestCann aims to leverage the same underlying product to deliver next-generation recreational cannabis products. The company’s wholly-owned Saskatchewan subsidiary has a Health Canada license enabling it to produce hemp cigarettes containing THC – one of the hottest segments of the recreational cannabis industry. 
Homogenized & Cost Effective
Based on proven tobacco technology, WestCann and its technology partners have designed and built a homogenization process for cannabis and hemp that reconstitutes and standardizes the plant material for fully automated high-speed manufacturing and packaging. The process separates the ingredients from the traditional horticultural cannabis crop cycles and completely commoditizes the supply chain, enabling any combination of strain flavors and THC/CBD profiles.
More importantly, the process creates significant cost advantages over conventional pre-roll production. These efficiencies will enable aggressive pricing to capture market share during early stages while providing attractive profit margins over the long term. As a result, the WestCann could quickly become a leader in the pre-rolled marijuana segment in Canada.
The company believes that its initial manufacturing line at its Yorkton, SK facility could produce approximately three million 10-packs of cannabis rolls each year in a single-shift operation. As all ingredients of WestCann’s products are fully commoditized, the company can rapidly scale up production by adding second or third shifts or more production lines and potentially even white-label products for others.
Experienced Management Team
Most early-stage, pre-revenue companies rely heavily on their management team and Board of Directors to provide credibility. After all, investors are contributing capital on a promise to build out a vision rather than looking at existing cash flow. Fortunately, WestCann has a very seasoned management team with direct industry experience.
CEO Andreas Gedeon has been a pioneer in the medical, pharmaceutical, and recreational cannabis industry since 2010. Before starting WestCann in August 2018, he was Managing Director of Australia’s first publicly traded cannabis company, MMJ Phytotech (ASX:MMJ), and founding CEO of Harvest One Cannabis (TSXV:HVT).
COO Nicholas Muellem has deep connections in big tobacco, having worked as the CEO of one of the industry’s leading equipment manufacturers. And General Manager Kelly Godlien has over 20 years of senior and executive management experience in finance and accounting, having worked with Tweet Grassland and Canopy Growth in the past.
Looking Ahead
With the US product line expected to launch by November 2021 and the Company’s Yorkton, SK facility being operational by January 2022, management is currently negotiating marketing and distribution agreements with several large industry players and is expecting a steady stream of milestone achievements coming up over the next couple of months.
Retail investors will see a public CSE listing in Q1 next year, while accredited investors may participate in the company’s current convertible debenture offering at 12% interest and a 20% conversion discount to the listing price. Contact info@westcann.com for more information or to join in the pre-public capital raise.
In the meantime, visit the company’s websites at www.WestCann.com and www.TryLaika.com, sign up to download the company’s investor presentation and receive a going public alert, so you don’t miss the opportunity!
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
CB Therapeutics, Inc. is a biotechnology company focusing on the innovative production of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems.
Resolve Digital Health Inc. committed to establishing a standard of care missing from the medical cannabis industry until now.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
